Abstract
Risperidone and remoxipride are recently introduced atypical antipsychotics, with clinical efficacy comparable to that of classical antipsychotics but lower propensity to induce extrapyramidal side effects (EPS). It is unclear whether these properties relate to weak dopamine D2 receptor blockade in vivo, as has been suggested for the archetypal atypical antipsychotic clozapine. We have used 123I-IBZM single photon emission tomography (SPET) to characterize the patterns of striatal D2 receptor binding in vivo in DSMIII-R-diagnosed schizophrenic and schizo-affective patients treated with either risperidone (n = 6) or remoxipride (n = 4) but predominantly EPS free. These groups were compared to age- and BPRS- matched subjects from a previously reported D2 receptor binding database of patients treated with clozapine (n = 10) and classical antipsychotics (n = 10). Patients on risperidone and remoxipride had high levels of D2 receptor blockade, comparable to those of patients on classical antipsychotics, and significantly greater than those obtained with clozapine-treated patients (risperidone versus clozapine, P < 0.005; remoxipride versus clozapine, P < 0.025). These results suggest high levels of striatal D2 receptor occupancy in ...Continue Reading
References
Jun 24, 1976·Nature·P SeemanK Wong
Jul 25, 1992·Lancet·L S PilowskyR W Kerwin
Jul 1, 1992·Archives of General Psychiatry·H Berenbaum
Mar 1, 1991·Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism·T BrückeL Deecke
Jan 1, 1991·Schizophrenia Bulletin·J Gerlach
Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·S O OgrenK Angeby-Möller
Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·L Farde, C von Bahr
Jan 1, 1990·Acta Psychiatrica Scandinavica. Supplementum·T LewanderD Morrison
Jan 1, 1990·The American Journal of Psychiatry·J L MartinotH Loo
Jan 1, 1989·Neuroscience·M CampsJ M Palacios
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1989·Psychopharmacology·H Hippius
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
Dec 1, 1980·The American Journal of Psychiatry·S J Peroutka, S H Synder
Jul 20, 1984·European Journal of Pharmacology·S O OgrenL Florvall
Dec 1, 1993·The British Journal of Psychiatry : the Journal of Mental Science·G F BusattoR W Kerwin
Jan 1, 1993·Psychopharmacology·S NybergB Eriksson
Jan 1, 1993·Psychopharmacology·J E LeysenA A Megens
Aug 1, 1993·Psychological Medicine·L S PilowskyR W Kerwin
Jan 1, 1994·The British Journal of Psychiatry : the Journal of Mental Science·L S PilowskyR W Kerwin
Jul 6, 1993·European Journal of Pharmacology·N MohellD M Jackson
Citations
Jul 1, 1995·European Journal of Nuclear Medicine·R W Kerwin, L S Pilowsky
Mar 1, 1996·Psychopharmacology·B J Kinon, J A Lieberman
Mar 1, 1996·Psychopharmacology·L S PilowskyR W Kerwin
Apr 1, 1997·Pharmacology, Biochemistry, and Behavior·K M TrimbleD J King
Dec 7, 2002·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Peter S Talbot, Marc Laruelle
Sep 1, 2001·Psychiatry Research·M BernardoM Salamero
Nov 25, 1996·Psychiatry Research·B KüfferleS Kasper
Sep 11, 1999·Psychiatry Research·T J RaedlerD R Weinberger
May 20, 2006·Journal of Sex & Marital Therapy·H KnegteringDurk Wiersma
Apr 1, 1999·Acta Psychiatrica Scandinavica·M BahroJ Strnad
Mar 1, 2000·Acta Neuropsychiatrica·H KnegteringC Ten Brink
Jan 1, 1997·Journal of Psychopharmacology·G P Reynolds
Sep 19, 2002·Journal of Psychopharmacology·G J E SchmittH J Möller
Mar 1, 2008·Journal of Psychopharmacology·A M CatafauUNKNOWN Barcelona Clinical Imaging in Psychiatry Group
Jan 1, 1997·Journal of Psychopharmacology·G F Busatto, R W Kerwin
May 5, 2000·The Cochrane Database of Systematic Reviews·A TuunainenS M Gilbody
Jan 25, 2003·Journal of Clinical Psychopharmacology·Rodrigo A BressanLyn S Pilowsky
Oct 19, 2001·CNS Drug Reviews·R Nadal